5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
A clinical breakdown of Saxenda (liraglutide 3 mg) compounding legality, FDA approval history, shortage list status, and the 503A/503B framework that governs compounded GLP-1 medications.
A clinician-focused review of Saxenda (liraglutide 3 mg) regulatory approvals across FDA, EMA, and other global agencies, including label details, post-market safety signals, and prescribing requirements.
A complete timeline of Saxenda (liraglutide 3 mg) FDA label updates from 2020 through 2026, including new safety warnings, boxed label revisions, post-market study results, and prescribing changes.
A clinical review of Saxenda (liraglutide 3 mg) legal and patent challenges, including FDA approval history, post-market safety signals, label changes, and Novo Nordisk patent litigation.
Saxenda's FDA NDA number is 206321, approved December 23, 2014. See the timeline, label changes, pediatric expansion, and post-market safety warnings.